ASCO/CAP 乳腺癌雌激素与孕激素受体检测指南更新
该指南更新由 ASCO/CAP 多学科国际专家组基于系统文献综述制定,继续推荐经认证的免疫组化检测 ER 作为预测内分泌治疗获益的标准,并将 1%–10% 阳性归为 ER 低阳性新报告类别,同时建议对 0%–10% 染色病例报告对照状态。
要点
- ER 检测采用经认证的免疫组化,作为预测内分泌治疗获益的标准。
- 1%–100% 肿瘤细胞核阳性为 ER 阳性,其中 1%–10% 应报告为 ER 低阳性。
- <1% 或 0% 肿瘤细胞核免疫反应为 ER 阴性,0%–10% 染色需报告对照状态。
核心结论
- 继续推荐经认证的免疫组化检测 ER 作为预测内分泌治疗获益的标准,不推荐其他检测用于此目的。
- 1%–100% 肿瘤细胞核阳性应判读为 ER 阳性,但 1%–10% 阳性者内分泌治疗获益数据有限。
- <1% 或 0% 肿瘤细胞核免疫反应判读为 ER 阴性。
研究设计与样本
- ASCO/CAP 召集多学科国际专家小组,基于系统文献综述更新临床实践指南推荐。
主要发现
- 专家小组承认 1%–10% 细胞 ER 阳性肿瘤的内分泌治疗获益数据有限。
- 对 0%–10% 染色病例应报告对照状态。
关键数值与推荐
- ER 阳性:1%–100% 肿瘤细胞核阳性;其中 1%–10% 应报告为 ER 低阳性并附推荐注释。
- ER 阴性:<1% 或 0% 肿瘤细胞核免疫反应。
- DCIS 推荐 ER 检测以评估内分泌治疗降低未来乳腺癌风险的潜在获益,PgR 检测为可选。
- PgR 检测主要用于 ER 阳性乳腺癌的预后目的。
临床怎么用
- 对浸润性乳腺癌采用经认证的免疫组化检测 ER 以指导内分泌治疗决策。
- 1%–10% ER 阳性应使用 ER 低阳性新报告类别并附推荐注释。
- 实验室应建立标准操作程序以确认或裁定初始低至无 ER 染色的结果。
局限性
- 1%–10% 细胞 ER 阳性肿瘤的内分泌治疗获益数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To update key recommendations of the American Society of Clinical Oncology/College of American Pathologists estrogen (ER) and progesterone receptor (PgR) testing in breast cancer guideline. METHODS: A multidisciplinary international Expert Panel was convened to update the clinical practice guideline recommendations informed by a systematic review of the medical literature. RECOMMENDATIONS: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose. Breast cancer samples with 1% to 100% of tumor nuclei positive should be interpreted as ER positive. However, the Expert Panel acknowledges that there are limited data on endocrine therapy benefit for cancers with 1% to 10% of cells staining ER positive. Samples with these results should be reported using a new reporting category, ER Low Positive, with a recommended comment. A sample is considered ER negative if < 1% or 0% of tumor cell nuclei are immunoreactive. Additional strategies recommended to promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result include establishing a laboratory-specific standard operating procedure describing additional steps used by the laboratory to confirm/adjudicate results. The status of controls should be reported for cases with 0% to 10% staining. Similar principles apply to PgR testing, which is used primarily for prognostic purposes in the setting of an ER-positive cancer. Testing of ductal carcinoma in situ (DCIS) for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional. Additional information can be found at www.asco.org/breast-cancer-guidelines.
引用
- Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020. PMID: 31928404. doi:10.1200/JCO.19.02309
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。